Table 1. Baseline characteristics and outcomes according to WMH severities.
| Characteristics | FAZEKAS score (n=787) | P value | ||
|---|---|---|---|---|
| 0–2 (n=355) | 3–4 (n=263) | 5–6 (n=169) | ||
| Age | 59.1±9.7 | 65.1±10.1 | 70.1±8.8 | <0.001 |
| BMI | 24.5±3.2 | 24.3±3.4 | 23.9±3.0 | 0.34 |
| Female | 104 (29.3%) | 105 (39.9%) | 64 (37.9%) | 0.01 |
| Medical history, No. (%) | ||||
| Ischemic stroke | 39 (11.0%) | 41 (15.6%) | 46 (27.2%) | <0.001 |
| TIA | 3 (0.8%) | 6 (2.3%) | 2 (1.2%) | 0.31 |
| Myocardial infarction | 4 (1.1%) | 6 (2.3%) | 7 (4.1%) | 0.08 |
| Atrial fibrillation or flutter | 4 (1.1%) | 5 (1.9%) | 7 (4.1%) | 0.07 |
| Hypertension | 202 (56.9%) | 180 (68.4%) | 121 (71.6%) | <0.001 |
| Hyperlipidemia | 43 (12.1%) | 30 (11.4%) | 18 (10.7%) | 0.88 |
| Diabetes mellitus | 79 (22.3%) | 53 (20.2%) | 36 (21.3%) | 0.82 |
| Current or previous smoking | 169 (47.6%) | 105 (39.9%) | 55 (32.5%) | <0.003 |
| Antiplatelet therapy, No. (%) | ||||
| Aspirin alone | 185 (52.1%) | 130 (49.4%) | 85 (50.3%) | 0.79 |
| Aspirin plus Clopidogrel | 170 (47.9%) | 133 (50.6%) | 84 (49.7%) | |
| Time to randomization | 13.0±6.7 | 13.7±6.7 | 13.9±6.5 | 0.25 |
| Other CSVD image markers | ||||
| Multiple CMBs† | 1 (0.3%) | 9 (3.4%) | 20 (11.8%) | <0.001 |
| Lacunes | 145 (41.3%) | 174 (66.7%) | 148 (88.6%) | <0.001 |
| Severe PVSs‡ | 148 (41.7%) | 161 (61.2%) | 123 (72.8%) | <0.001 |
| Outcomes | ||||
| NIHSS | ||||
| 0–1 | 123 (34.6%) | 91 (34.6%) | 44 (26.0%) | 0.11 |
| 2–3 | 232 (65.4%) | 172 (65.4%) | 125 (74.0%) | |
| mRS | ||||
| 0–1 | 322 (90.7) | 221 (84.0%) | 147 (87.0%) | 0.04 |
| 2–6 | 33 (9.3) | 42 (16.0) | 22 (13.0%) | |
| Ischemic stroke | 30 (8.5%) | 31 (11.8%) | 13 (7.7%) | 0.26 |
| Hemorrhage stroke | 0 | 0 | 0 | – |
†, multiple CMBs: cerebral microbleeds ≥5; ‡, severe PVSs: >10 perivascular spaces in the basal ganglia, or >20 in the centrum semiovale.